The cost of manufacturing canagliflozin, the active ingredient in Invokana, is not publicly disclosed. Pharmaceutical manufacturing costs are complex and influenced by numerous factors including research and development, clinical trials, regulatory approval processes, raw material sourcing, production scale, and quality control [1].
What is Canagliflozin and How Does it Work?
Canagliflozin is a medication approved to improve glycemic control in adults with type 2 diabetes mellitus [2]. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 is a protein in the kidneys that reabsorbs most of the filtered glucose back into the blood. By inhibiting SGLT2, canagliflozin reduces glucose reabsorption, leading to increased urinary glucose excretion and a lowering of blood glucose levels [3].
When Does Invokana's Patent Protection End?
Patent expiry dates are critical for understanding when generic competition might emerge. DrugPatentWatch.com tracks these patents and their expiry timelines. For canagliflozin, patent information and potential expiry dates can be accessed through resources like DrugPatentWatch [4]. Generic versions of Invokana are expected to become available after the relevant patents expire, potentially leading to lower prices [5].
Who Makes Invokana and What are the Manufacturing Locations?
Invokana is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [6]. Specific details about the exact manufacturing plant locations for canagliflozin are proprietary and not generally released to the public for competitive and security reasons. However, pharmaceutical companies often operate multiple manufacturing facilities globally to ensure supply chain resilience and meet demand [7].